Dynavax Technologies Corporation Market Cap ($1.76 Billion)
Market Cap & Net Worth: Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation market cap. Dynavax Technologies Corporation (NASDAQ:DVAX) has a market capitalization of $1.76 Billion ($1.76 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6336 globally and #2034 in its home market, demonstrating a 0.10% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dynavax Technologies Corporation's stock price $15.50 by its total outstanding shares 113684064 (113.68 Million). Also see how efficiently does Dynavax Technologies Corporation generate cash for how efficiently the company converts equity into cash flow.
Dynavax Technologies Corporation Market Cap History (2015–2026)
Dynavax Technologies Corporation market cap history from 2015 to 2026. Data shows change from $2.75 Billion to $1.76 Billion (-4.28% CAGR). Check current stock price of Dynavax Technologies Corporation for real-time trading data and today's change.
Index Memberships
Dynavax Technologies Corporation is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.07% | #181 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #715 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.10% | #109 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.56 Trillion | 0.12% | #342 of 602 |
Weight: Dynavax Technologies Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dynavax Technologies Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dynavax Technologies Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Dynavax Technologies Corporation (DVAX) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.24x
Dynavax Technologies Corporation's market cap is 5.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
53.16x
Dynavax Technologies Corporation's market cap is 53.16 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.75 Billion | $4.05 Million | -$106.79 Million | 678.17x | N/A |
| 2016 | $449.05 Million | $11.04 Million | -$112.44 Million | 40.66x | N/A |
| 2017 | $2.13 Billion | $327.00K | -$95.15 Million | 6501.20x | N/A |
| 2018 | $1.04 Billion | $8.20 Million | -$158.90 Million | 126.89x | N/A |
| 2019 | $650.27 Million | $35.22 Million | -$152.60 Million | 18.46x | N/A |
| 2020 | $505.89 Million | $46.55 Million | -$75.24 Million | 10.87x | N/A |
| 2021 | $1.60 Billion | $439.44 Million | $76.71 Million | 3.64x | 20.85x |
| 2022 | $1.21 Billion | $722.68 Million | $293.16 Million | 1.67x | 4.13x |
| 2023 | $1.59 Billion | $232.28 Million | -$6.39 Million | 6.84x | N/A |
| 2024 | $1.45 Billion | $277.25 Million | $27.31 Million | 5.24x | 53.16x |
Competitor Companies of DVAX by Market Capitalization
Companies near Dynavax Technologies Corporation in the global market cap rankings as of November 1, 2026. Also see Dynavax Technologies Corporation (DVAX) total assets for a full breakdown of the balance sheet.
Key companies related to Dynavax Technologies Corporation by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Dynavax Technologies Corporation (2015–2026)
Market capitalization of Dynavax Technologies Corporation from 2015 to today. Between 2015 and today, Dynavax Technologies Corporation's market cap moved from $2.75 Billion to $ 1.76 Billion, with a yearly change of -4.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.76 Billion | +0.78% |
| 2025 | $1.75 Billion | +20.44% |
| 2024 | $1.45 Billion | -8.66% |
| 2023 | $1.59 Billion | +31.39% |
| 2022 | $1.21 Billion | -24.38% |
| 2021 | $1.60 Billion | +216.18% |
| 2020 | $505.89 Million | -22.20% |
| 2019 | $650.27 Million | -37.49% |
| 2018 | $1.04 Billion | -51.07% |
| 2017 | $2.13 Billion | +373.42% |
| 2016 | $449.05 Million | -83.65% |
| 2015 | $2.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Dynavax Technologies Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.76 Billion USD |
| MoneyControl | $1.76 Billion USD |
| MarketWatch | $1.76 Billion USD |
| marketcap.company | $1.76 Billion USD |
| Reuters | $1.76 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more